The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelialmesenchymal transition of lens epithelial cells

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Chen, X ^a   Xiao, W ^a   Chen, W ^a   Luo, L ^a   Ye, S ^a   Liu, Y ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Anterior subcapsular cataract (ASC); Epithelialmesenchymal transition (EMT); Histone deacetylase inhibitor; Lens epithelium cells (LECs); Posterior capsule opacification (PCO); Proliferation

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 4; CYCLIN DEPENDENT KINASE; FIBRONECTIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NERVE CELL ADHESION MOLECULE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; SMAD2 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA2; TRICHOSTATIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LENS EPITHELIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SUBCAPSULAR CATARACT; UPREGULATION;

ACETYLATION; CATARACT; CELL CYCLE CHECKPOINTS; CELL MOVEMENT; CELL PROLIFERATION; EPIGENESIS, GENETIC; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; LENS, CRYSTALLINE; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, NOTCH; SMAD2 PROTEIN; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA2; UP-REGULATION;

EID: 84887463245     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.416     Document Type: Article

References (41)

1. McCarty CA, Taylor HR. Recent developments in vision research: Light damage in cataract. Invest Ophthalmol Vis Sci 1996; 37: 1720-1723
2. Nathu Z, Dwivedi DJ, Reddan JR, Sheardown H, Margetts PJ, West-Mays JA. Temporal changes in MMP mRNA expression in the lens epithelium during anterior subcapsular cataract formation. Exp Eye Res 2009; 88: 323-330
3. Shin EH, Basson MA, Robinson ML, McAvoy JW, Lovicu FJ. Sprouty is a negative regulator of transforming growth factor beta-induced epithelial-to-mesenchymal transition and cataract. Mol Med 2012; 18: 861-873
4. Apple DJ, Solomon KD, Tetz MR, Assia EI, Holland EY, Legler UF et al. Posterior capsule opacification. Surv Ophthalmol 1992; 37: 73-116
5. Hodge WG. Posterior capsule opacification after cataract surgery. Ophthalmology 1998; 105: 943-944
6. Srinivasan Y, Lovicu FJ, Overbeek PA. Lens-specific expression of transforming growth factor beta1 in transgenic mice causes anterior subcapsular cataracts. J Clin Invest 1998; 101: 625-634
7. de Iongh RU, Wederell E, Lovicu FJ, McAvoy JW. Transforming growth factorbeta-induced epithelial-mesenchymal transition in the lens: A model for cataract formation. Cells Tissues Organs 2005; 179: 43-55
8. Wallentin N, Wickstrom K, Lundberg C. Effect of cataract surgery on aqueous TGF-beta and lens epithelial cell proliferation. Invest Ophthalmol Vis Sci 1998; 39: 1410-1418
9. Meacock WR, Spalton DJ, Stanford MR. Role of cytokines in the pathogenesis of posterior capsule opacification. Br J Ophthalmol 2000; 84: 332-336
10. Allen JB, Davidson MG, Nasisse MP, Fleisher LN, McGahan MC. The lens influences aqueous humor levels of transforming growth factor-beta 2. Graefes Arch Clin Exp Ophthalmol 1998; 236: 305-311
11. Awasthi N, Guo S, Wagner BJ. Posterior capsular opacification: A problem reduced but not yet eradicated. Arch Ophthalmol 2009; 127: 555-562
12. Reichert N, Choukrallah MA, Matthias P. Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell Mol Life Sci 2012; 69: 2173-2187
13. Tang J, Yan H, Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond) 2013; 124: 651-662
14. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 2005; 25: 1608-1619
15. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003; 278: 12579-12589
16. Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012; 6: 579-589
17. Rombouts K, Niki T, Greenwel P, Vandermonde A, Wielant A, Hellemans K et al. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res 2002; 278: 184-197
18. Van Beneden K, Geers C, Pauwels M, Mannaerts I, Wissing KM, Van den Branden C et al. Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. Toxicol Appl Pharmacol 2013; 271: 276-284
19. Niki T, Rombouts K, De Bleser P, De Smet K, Rogiers V, Schuppan D et al. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology 1999; 29: 858-867
20. Lei W, Zhang K, Pan X, Hu Y, Wang D, Yuan X et al. Histone deacetylase 1 is required for transforming growth factor-beta1-induced epithelial-mesenchymal transition. Int J Biochem Cell Biol 2010; 42: 1489-1497
21. Yoshikawa M, Hishikawa K, Marumo T, Fujita T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol 2007; 18: 58-65
22. Rishikof DC, Ricupero DA, Liu H, Goldstein RH. Phenylbutyrate decreases type I collagen production in human lung fibroblasts. J Cell Biochem 2004; 91: 740-748
23. Kerl K, Ries D, Unland R, Borchert C, Moreno N, Hasselblatt M et al. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. BMC Cancer 2013; 13: 286
24. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: New data on targeted therapies. Curr Oncol Rep 2012; 14: 129-138
25. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405
26. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119: 1429-1437
27. Wang Z, Li Y, Kong D, Sarkar FH. The role of Notch signaling pathway in epithelialmesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets 2010; 11: 745-751
28. Hales AM, Chamberlain CG, McAvoy JW. Cataract induction in lenses cultured with transforming growth factor-beta. Invest Ophthalmol Visual Sci 1995; 36: 1709-1713
29. Hallstrom TC, Nevins Jr. Balancing the decision of cell proliferation and cell fate. Cell Cycle 2009; 8: 532-535
30. Gulappa T, Reddy RS, Suman S, Nyakeriga AM, Damodaran C. Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cells. Cancer Lett 2013; 337: 177-183
31. Choi J, Park SY, Joo CK. Hepatocyte growth factor induces proliferation of lens epithelial cells through activation of ERK1/2 and JNK/SAPK. Invest Ophthalmol Visual Sci 2004; 45: 2696-2704
32. Jiang Q, Zhou C, Bi Z, Wan Y. EGF-induced cell migration is mediated by ERK and PI3K/AKT pathways in cultured human lens epithelial cells. J Ocul Pharmacol Ther 2006; 22: 93-102
33. Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS et al. Expression of histone deacetylases in lymphoma: Implication for the development of selective inhibitors. Br J Haematol 2009; 147: 515-525
34. Al-Janadi A, Chandana SR, Conley BA. Histone deacetylation: An attractive target for cancer therapy? Drugs R&D 2008; 9: 369-383
35. Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol 2009; 297: V729-F739
36. Wu MZ, Tsai YP, Yang MH, Huang CH, Chang SY, Chang CC et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol Cell 2011; 43: 811-822
37. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 2012; 11: 790-811
38. Choi ME, Ding Y, Kim SI. TGF-beta signaling via TAK1 pathway: Role in kidney fibrosis. Sem Nephrol 2012; 32: 244-252
39. Leask A. Targeting the jagged/notch pathway: A new treatment for fibrosis? J Cell Commun Signaling 2010; 4: 197-198
40. Connor TB Jr, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 1989; 83: 1661-1666
41. Hales AM, Chamberlain CG, McAvoy JW. Susceptibility to TGFbeta2-induced cataract increases with aging in the rat. Invest Ophthalmol Vis Sci 2000; 41: 3544-3551